A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 315 participants.

Also called NCT07848880

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 315 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07848880
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07848880. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2028-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
Condition
Hypertriglyceridemia
Intervention (Drug)
DR10624 Injection
Intervention (Drug)
Placebo
Lead sponsor
Zhejiang Doer Biologics Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07848880
Content hash
4687a7090b6dd84d5f596870977b508e4a3979d45c215ba5cd8fc904e849070e